Last reviewed · How we verify
OCU410ST
At a glance
| Generic name | OCU410ST |
|---|---|
| Sponsor | Ocugen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OCU410ST CI brief — competitive landscape report
- OCU410ST updates RSS · CI watch RSS
- Ocugen portfolio CI